Egyptian International Pharmaceutical Investments (CAI:PHAR) Short Interest


CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
69 GF Score
Price E£85.22
GF Value E£59.67
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CAI:PHAR vs ZTS, UTHR, VTRS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's Short Interest distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's Short Interest falls into.


CAI:PHAR
69GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£85.22 is trading 42.8% above its estimated GF Value™ of E£59.67. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • Short Interest:
  • GF Value™: E£59.67 vs. price of E£85.22 (42.8% above fair value)
  • GF Score™: 69/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
69GF Score

Get the complete analysis for CAI:PHAR

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£85.22
Price
E£59.67
GF Value